Micronized Insulin Particle Formation via pH Titration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for micronizing insulin for pulmonary delivery often involve heat, excipient polymers, and harsh sterilization processes, which can lead to aggregation, degradation, and introduction of impurities, compromising the stability and efficacy of insulin particles.
Innovation Solution
A process involving dissolving insulin in an acidic environment, titrating with a buffer solution to form micronized particles, and stabilizing with an organic solvent at room temperature, avoiding the use of polymers and high temperatures, to produce spherical particles with a diameter of 1.2 to 2 µm, suitable for pulmonary delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If heat and harsh sterilization processes are used for micronizing insulin, then sterilization effectiveness is improved, but insulin stability and biological activity deteriorate due to aggregation and degradation
Solution Approach 1:
The patent changes the temperature parameter from high-heat sterilization to room temperature processing, and adjusts the pH parameter using buffer solutions to maintain insulin stability while achieving sterilization without causing aggregation or degradation
Solution Approach 2:
The patent introduces buffer solutions as intermediary substances that mediate between the need for sterilization and the requirement to maintain insulin stability, allowing the process to proceed at room temperature without direct harsh sterilization that would damage the insulin
2Manufacturing precision
If excipient polymers are used in micronization processes, then particle formation is improved, but product purity deteriorates due to introduction of impurities
Solution Approach 1:
The patent extracts or removes excipient polymers from the micronization process entirely, achieving particle formation through alternative mechanisms (pH adjustment and buffer solutions) that do not require polymer additives, thereby maintaining product purity
Solution Approach 2:
The patent uses disposable buffer solutions and acidic environments that can be easily removed or neutralized, replacing persistent polymer excipients with temporary reagents that facilitate particle formation but do not remain as impurities in the final product
3Manufacturing precision
If conventional micronization methods are used, then particle size reduction is achieved, but manufacturing complexity increases due to multiple harsh processing steps
Solution Approach 1:
The patent performs preliminary dissolution of insulin in acidic solution before micronization, creating a homogeneous precursor that facilitates easier and more controlled particle formation in subsequent steps, reducing the need for multiple harsh processing operations
Solution Approach 2:
The patent changes the pH parameter during the process to control particle formation and size, using buffer solutions to achieve the desired micronized particle characteristics without requiring multiple mechanical or thermal processing steps
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method ensures simpler and safer manufacturing, maintains biological activity, reduces aggregation, and achieves high recovery rates of micronized insulin particles with improved stability and purity for effective pulmonary delivery.
Implementation Method 1
dissolving an insulin raw material in an acidic environment to form a dissolved insulin solution
Implementation Method 2
titrating the dissolved insulin solution with a buffer solution to form a suspension including micronized insulin particles
Implementation Method 3
adding a stabilizing agent to stabilize the micronized insulin particles
Data Source
Figure 1
Figure 2
Figure 3
AI summary
A method of preparing an inhalable insulin suitable for pulmonary delivery includes: dissolving an insulin raw material in an acidic solution to form a dissolved insulin solution; titrating the dissolved insulin solution with a buffer solution to form a suspension comprising micronized insulin particles; and stabilizing the micronized insulin particles.